【正文】
IRSTLINE THERAPY option for invasive candidiasis while voriconazole was only remended as secondline therapy for esophageal candidiasis. 有力的念珠菌屬感染治療的對(duì)比數(shù)據(jù)證明科賽斯在侵入性念珠菌血癥可以作為一線的治療藥物,而同時(shí)伏立康唑僅被推薦作為食道念珠菌感染的二線治療藥物 ? Echinocandins are different because the strength of the data available to support its remendation. Evidence based medicine suggests that CANCIDAS should be the preferred echinocandin. 由于強(qiáng)有力的數(shù)據(jù)支持棘白菌素作為推薦的藥物。尋證醫(yī)學(xué)表明科賽斯應(yīng)該是優(yōu)先選擇的棘白菌素類藥物。